Skip to main content
. 2019 Aug 31;11:76. doi: 10.1186/s13195-019-0529-5

Fig. 2.

Fig. 2

Spectrum of AD and the corresponding cognitive and biomarker state of trial participants (A, amyloid abnormalities; T, tau abnormalities; N, neurodegeneration)